Cellectis SA
CLLS3.005USD
+0.055+1.86%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
216.64MCap. mercado
PérdidaP/E TTM
Más Datos de Cellectis SA Compañía
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Información de la empresa
Símbolo de cotizaciónCLLS
Nombre de la empresaCellectis SA
Fecha de salida a bolsaFeb 06, 2007
Director ejecutivoDr. David Sourdive, Ph.D.
Número de empleados224
Tipo de seguridadDepository Receipt
Fin del año fiscalFeb 06
Dirección8, rue de la Croix Jarry
CiudadPARIS
Bolsa de valoresNASDAQ Global Market Consolidated
PaísFrance
Código postal75013
Teléfono33181691600
Sitio Webhttps://www.cellectis.com/
Símbolo de cotizaciónCLLS
Fecha de salida a bolsaFeb 06, 2007
Director ejecutivoDr. David Sourdive, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Andre C. Muller
Mr. Andre C. Muller
Director
Director
--
--
Dr. Adrian Kilcoyne, M.D.
Dr. Adrian Kilcoyne, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Ms. Kyung Nam-Wortman
Ms. Kyung Nam-Wortman
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
--
--
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Non-Executive Director
Non-Executive Director
--
--
Dr. Cecile Chartier, Ph.D.
Dr. Cecile Chartier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Andre C. Muller
Mr. Andre C. Muller
Director
Director
--
--
Dr. Adrian Kilcoyne, M.D.
Dr. Adrian Kilcoyne, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Ms. Kyung Nam-Wortman
Ms. Kyung Nam-Wortman
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
France
41.51M
0.00%
Other
0.00
0.00%
USA
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: lun., 26 de may
Actualizado: lun., 26 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Long Focus Capital Management LLC
6.53%
B Group, Inc.
4.50%
UBS Asset Management (Switzerland)
3.98%
Pfizer Inc
3.86%
UBS Asset Management (Americas) LLC
2.55%
Other
78.58%
Accionistas
Accionistas
Proporción
Long Focus Capital Management LLC
6.53%
B Group, Inc.
4.50%
UBS Asset Management (Switzerland)
3.98%
Pfizer Inc
3.86%
UBS Asset Management (Americas) LLC
2.55%
Other
78.58%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
14.08%
Hedge Fund
6.68%
Corporation
3.86%
Investment Advisor/Hedge Fund
0.49%
Research Firm
0.18%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
74.66%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
78
18.32M
25.34%
-2.37M
2025Q1
83
18.44M
25.50%
-2.58M
2024Q4
88
17.72M
24.57%
+1.29M
2024Q3
106
16.31M
22.62%
-2.61M
2024Q2
105
14.76M
20.47%
-2.65M
2024Q1
113
14.77M
20.56%
-2.69M
2023Q4
124
14.69M
20.46%
-8.13M
2023Q3
142
13.62M
24.51%
-10.91M
2023Q2
155
16.13M
29.02%
-9.56M
2023Q1
162
17.33M
31.20%
-2.13M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Long Focus Capital Management LLC
4.72M
6.53%
+100.00K
+2.17%
Mar 31, 2025
B Group, Inc.
3.26M
4.5%
+175.00K
+5.68%
Mar 31, 2025
UBS Asset Management (Switzerland)
2.88M
3.98%
+1.44M
+100.00%
Mar 31, 2025
Pfizer Inc
2.79M
3.86%
+2.79M
--
Dec 31, 2023
UBS Asset Management (Americas) LLC
1.85M
2.55%
+1.85M
--
Mar 31, 2025
UBS Asset Management Switzerland AG
1.44M
1.99%
--
--
Jan 31, 2025
Macquarie Investment Management
226.88K
0.31%
--
--
Mar 31, 2025
Bellecapital AG
226.07K
0.31%
--
--
Nov 30, 2024
Baillie Gifford & Co.
139.05K
0.19%
-151.38K
-52.12%
Mar 31, 2025
Millennium Management LLC
103.85K
0.14%
-430.70K
-80.57%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ActivePassive International Equity ETF
0%
Avantis International Equity ETF
0%
ActivePassive International Equity ETF
Proporción0%
Avantis International Equity ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
